2514 related articles for article (PubMed ID: 19433655)
21. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial.
Möller JC; Oertel WH; Köster J; Pezzoli G; Provinciali L
Mov Disord; 2005 May; 20(5):602-10. PubMed ID: 15726540
[TBL] [Abstract][Full Text] [Related]
22. Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial.
Nutt JG; Carter JH; Carlson NE
Arch Neurol; 2007 Mar; 64(3):319-23. PubMed ID: 17353373
[TBL] [Abstract][Full Text] [Related]
23. Risk factors for somnolence, edema, and hallucinations in early Parkinson disease.
Biglan KM; Holloway RG; McDermott MP; Richard IH;
Neurology; 2007 Jul; 69(2):187-95. PubMed ID: 17620552
[TBL] [Abstract][Full Text] [Related]
24. Sodium oxybate for excessive daytime sleepiness in Parkinson disease: an open-label polysomnographic study.
Ondo WG; Perkins T; Swick T; Hull KL; Jimenez JE; Garris TS; Pardi D
Arch Neurol; 2008 Oct; 65(10):1337-40. PubMed ID: 18852348
[TBL] [Abstract][Full Text] [Related]
25. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
26. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A
Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848
[TBL] [Abstract][Full Text] [Related]
27. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD.
Katzenschlager R; Head J; Schrag A; Ben-Shlomo Y; Evans A; Lees AJ;
Neurology; 2008 Aug; 71(7):474-80. PubMed ID: 18579806
[TBL] [Abstract][Full Text] [Related]
28. Pramipexole v. levodopa as initial treatment for Parkinson's disease: a randomized clinical-economic trial.
Noyes K; Dick AW; Holloway RG;
Med Decis Making; 2004; 24(5):472-85. PubMed ID: 15358996
[TBL] [Abstract][Full Text] [Related]
29. The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group.
LeWitt P; Oakes D; Cui L
Mov Disord; 1997 Mar; 12(2):183-9. PubMed ID: 9087976
[TBL] [Abstract][Full Text] [Related]
30. Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson's disease: impact on control of fluctuations and quality of life.
Puente V; De Fabregues O; Oliveras C; Ribera G; Pont-Sunyer C; Vivanco R; Cucurella G; Giralt E; Delgado T; Garcia C; Seoane A; Campo R
Parkinsonism Relat Disord; 2010 Mar; 16(3):218-21. PubMed ID: 19762271
[TBL] [Abstract][Full Text] [Related]
31. [Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy].
Buchwald B; Angersbach D; Jost WH
Fortschr Neurol Psychiatr; 2007 Apr; 75(4):236-41. PubMed ID: 17427044
[TBL] [Abstract][Full Text] [Related]
32. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial.
Goetz CG; Damier P; Hicking C; Laska E; Müller T; Olanow CW; Rascol O; Russ H
Mov Disord; 2007 Jan; 22(2):179-86. PubMed ID: 17094088
[TBL] [Abstract][Full Text] [Related]
33. Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial.
Poewe W; Rascol O; Barone P; Hauser RA; Mizuno Y; Haaksma M; Salin L; Juhel N; Schapira AH;
Neurology; 2011 Aug; 77(8):759-66. PubMed ID: 21832218
[TBL] [Abstract][Full Text] [Related]
34. Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage.
Giménez-Roldán S; Tolosa E; Burguera JA; Chacón J; Liaño H; Forcadell F
Clin Neuropharmacol; 1997 Feb; 20(1):67-76. PubMed ID: 9037575
[TBL] [Abstract][Full Text] [Related]
35. AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials.
Berg D; Godau J; Trenkwalder C; Eggert K; Csoti I; Storch A; Huber H; Morelli-Canelo M; Stamelou M; Ries V; Wolz M; Schneider C; Di Paolo T; Gasparini F; Hariry S; Vandemeulebroecke M; Abi-Saab W; Cooke K; Johns D; Gomez-Mancilla B
Mov Disord; 2011 Jun; 26(7):1243-50. PubMed ID: 21484867
[TBL] [Abstract][Full Text] [Related]
36. Dopamine agonist withdrawal syndrome in Parkinson disease.
Rabinak CA; Nirenberg MJ
Arch Neurol; 2010 Jan; 67(1):58-63. PubMed ID: 20065130
[TBL] [Abstract][Full Text] [Related]
37. Long-duration response to levodopa in patients with advanced Parkinson disease treated with subthalamic deep brain stimulation.
Wider C; Russmann H; Villemure JG; Robert B; Bogousslavsky J; Burkhard PR; Vingerhoets FJ
Arch Neurol; 2006 Jul; 63(7):951-5. PubMed ID: 16831963
[TBL] [Abstract][Full Text] [Related]
38. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.
Parkinson Study Group
JAMA; 2002 Apr; 287(13):1653-61. PubMed ID: 11926889
[TBL] [Abstract][Full Text] [Related]
39. Rationale for delayed-start study of pramipexole in Parkinson's disease: the PROUD study.
Schapira AH; Albrecht S; Barone P; Comella CL; McDermott MP; Mizuno Y; Poewe W; Rascol O; Marek K
Mov Disord; 2010 Aug; 25(11):1627-32. PubMed ID: 20544810
[TBL] [Abstract][Full Text] [Related]
40. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D
Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
